Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SMO


Brief Information

Name:Smoothened receptor
Target Synonym:SMO,SMOH,Smoothened, Frizzled Class Receptor,Smoothened, Frizzled Family Receptor,Frizzled Family Member 11,Protein Gx,Seven Transmembrane Helix Receptor,Smoothened Homolog (Drosophila),Smoothened Homolog,FZD11,CRJS,Gx,Smoothened Receptor,Smoothened, Seven Transmembrane Spanning Receptor,Smoothened (Drosophila) Homolog
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SMO-H52P3 Human Human SMO Full Length Protein (VLP)
ACRO Quality

Part of Bioactivity data


Immobilized Human SMO Full Length Protein-VLP (Cat. No. SMO-H52P3) at 10 μg/mL (100 μL/well) can bind Anti-SMO antibody with a linear range of 0.01-2.5 μg/mL (QC tested).

Synonym Name

SMO,smoothened, frizzled class receptor,CRJS, FZD11, Gx, PHLS, SMOH


Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sonidegib Diphosphate LDE-225; NVP-LDE-225 Approved Novartis Pharma Ag Odomzo, 奥昔朵 United States Carcinoma, Basal Cell Sun Pharmaceutical Industries Ltd 2015-07-24 Colorectal Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Myeloproliferative Disorders; Blood Platelet Disorders; Multiple Myeloma; Basal Cell Nevus Syndrome; Prostatic Neoplasms; Breast Neoplasms; Neuroblastoma; Thrombocytosis; Primary Myelofibrosis; Pancreatic Neoplasms; Astrocytoma; Hepatic Insufficiency; Bone Marrow Diseases; Carcinoma, Pancreatic Ductal; Leukemia, Myeloid, Acute; Lung Neoplasms; Glioma; Carcinoma, Hepatocellular; Thrombocythemia, Essential; Adenocarcinoma; Carcinoma, Basal Cell; Ovarian Neoplasms; Solid tumours; Hematologic Neoplasms; Rhabdomyosarcoma; Leukemia; Medulloblastoma; Blood Coagulation Disorders; Hemorrhagic Disorders; Hematologic Diseases; Leukemia, Myelogenous, Chronic; Bone Marrow Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Hepatoblastoma; Stomach Neoplasms; Triple Negative Breast Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Fibrosis; Skin Neoplasms Details
Glasdegib PF-04; PF-4449913; PF-04449913 Approved Pfizer Inc Daurismo United States Leukemia, Myeloid, Acute Pfizer Inc 2018-11-21 Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Graft vs Host Disease; Kidney Diseases; Neoplasms; Hepatic Insufficiency; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Fasciitis Details
Vismodegib R-3616; RG-3616; GDC-0449 Approved Genentech Inc, F. Hoffmann-La Roche Ltd Erivedge United States Carcinoma, Basal Cell Genentech Inc 2012-01-30 Gastrointestinal Stromal Tumors; Liposarcoma; Chondrosarcoma, Clear Cell; Basal Cell Nevus Syndrome; Neurofibrosarcoma; Sarcoma; Breast Neoplasms; Osteosarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Brain Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Gliosarcoma; Colorectal Neoplasms; Sarcoma, Synovial; Lymphoma, Non-Hodgkin; Lymphoma; Carcinoma, Pancreatic Ductal; Leukemia, Myeloid, Acute; Uterine Neoplasms; Chondrosarcoma, Mesenchymal; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma; Sarcoma, Kaposi; Neuroectodermal Tumors, Primitive, Peripheral; Adenocarcinoma; Hemangioendothelioma, Epithelioid; Stomach Neoplasms; Leiomyosarcoma; Rhabdomyosarcoma; Medulloblastoma; Ovarian Neoplasms; Chondrosarcoma; Fibrosarcoma; Hematologic Neoplasms; Carcinoma, Basal Cell; Hemangiosarcoma; Desmoplastic Small Round Cell Tumor; Mesenchymoma; Carcinoma, Renal Cell; Esophageal Neoplasms; Solid tumours; Odontogenic Cyst, Calcifying; Graft vs Host Disease; Skin Neoplasms; Lymphoma, Large B-Cell, Diffus Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Patidegib SGT-610; BBP-009; FIN-5; IPI-926 Phase 3 Clinical Infinity Pharmaceuticals Inc Chondrosarcoma; Head and Neck Neoplasms; Carcinoma, Basal Cell; Neoplasms; Pancreatic Neoplasms; Basal Cell Nevus Syndrome; Primary Myelofibrosis; Adenocarcinoma Details
Taladegib RXDX-109; ENV-IPF-101; ENV-ONC-101; LY-2940680; ENV-101 Phase 2 Clinical Eli Lilly And Company Solid tumours; Medulloblastoma; Rhabdomyosarcoma; Idiopathic Pulmonary Fibrosis; Colonic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Cholangiocarcinoma; Sarcoma; Breast Neoplasms; Neoplasm Metastasis Details
GT-1708F GT-1708; GT1708F; GT-1708F Phase 2 Clinical Suzhou Koshine Biomedica Inc Hematologic Neoplasms; Solid tumours; Idiopathic Pulmonary Fibrosis Details
Cipromedegib SHR-1539 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details
ZSP-1602 ZSP-1602 Phase 1 Clinical Guangdong Zhongsheng Pharmaceutical Co Ltd Medulloblastoma; Carcinoma; Carcinoma, Basal Cell; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Neuroendocrine Tumors; Glioma; Adenocarcinoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message